NEWTOWN, PA / ACCESSWIRE / October 2, 2014 / Helius Medical Technologies, Inc. (CSE: HSM) ("HMT", "Helius" or the "Company") is pleased to announce today that it has obtained investigational testing authorization from Health Canada for its PoNSTM device. Helius intends to initiate a study of the PoNSTM device in the treatment of symptoms associated with Multiple Sclerosis ("MS"). On institutional review board (IRB) approval, this study is scheduled to commence at the Montreal Neurological Institute. The PoNSTM, an investigational medical device that induces neuromodulation by stimulating the cranial nerves found in the tongue, is initially being studied for the treatment of balance disorder symptoms caused by Traumatic Brain Injury ("TBI") and MS.
"Part of the business strategy at Helius is to test the PoNSTM device against neurological symptoms of varying etiologies including trauma (as in TBI), progressive disease (as exampled with MS) and potentially a cognitive disorder (such as in Alzheimer's disease). We are excited to be working with the Montreal Neurological Institute, a world class center for MS research, as we continue to execute on this strategy and direct resources towards this debilitating disease," said Philippe Deschamps, Chief Executive Officer of Helius.
About Helius Medical Technologies
Helius Medical Technologies is a medical technology holding company focused on neurological wellness. HMT seeks to use unique and non-invasive platform technologies that create portals to the brain to amplify its ability to heal itself. HMT intends to file for U.S. Food and Drug Administration clearance for the PoNS(TM) device. For more information, please visit www.heliusmedical.com.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Safe Harbor Statement
All statements in this news release, other than statements of historical facts, are forward-looking statements. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include risks detailed from time to time in the filings made by the Company with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements except as required by applicable law.
# # #
Contact: Investor Relations:
778-588-7144
Corporate Contact:
Phil Deschamps
614-596-2597
Media Contact:
Becky Kern
914-772-2310
SOURCE: Helius Medical Technologies, Inc.